InvestorsHub Logo
Followers 104
Posts 13803
Boards Moderated 1
Alias Born 01/23/2004

Re: Thirdeyeblind post# 11203

Saturday, 03/10/2018 3:59:17 PM

Saturday, March 10, 2018 3:59:17 PM

Post# of 12606
Sure they would, happens all the time in big Pharma, but instead of buyout they set up partnerships.

Why would anyone buy out BICX and then spend 10 million more, minimum to try and gain few approval with no guarantees? They wouldn't



Ardm had a inhaled insulin product in clinical studies. Novartis went in a partnership with them to help develop the product, After Novartis spent 42 million dollars and had the product in the final stages of phase III, Novartis dropped the product because Pfizer's brand inhaled insulin (which made it to market first) was deemed to cause lung cancer turning the public off to inhaled insulin products.

A good example going on now is CNAT and Novartis.

The point being if a company gets to a certain level (BICX) where it looks like their product will get thought the clinical trials (bicx102) and will have of a good chance to make it to market and that product has a big market (fighting opiate addition) big Pharma companies are willing to gamble 10's of millions for a piece of that 10's of billions market.

And if you listen to the conference call carefully BICX has a company that is looking to partner with them, now that they go to move forward ruling from the FDA.

CC 54:40 to 55:20 IMPORTANT TO LISTEN VERY CAREFULLY TO WHAT HE IS SAYING